These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 17031404)

  • 1. Genetic and metabolic predictors of chemosensitivity in oligodendroglial neoplasms.
    Walker C; Haylock B; Husband D; Joyce KA; Fildes D; Jenkinson MD; Smith T; Broome J; Kopitzki K; du Plessis DG; Prosser J; Vinjamuri S; Warnke PC
    Br J Cancer; 2006 Nov; 95(10):1424-31. PubMed ID: 17031404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
    Walker C; Haylock B; Husband D; Joyce KA; Fildes D; Jenkinson MD; Smith T; Broome J; du Plessis DG; Warnke PC
    Neurology; 2006 Jun; 66(11):1661-7. PubMed ID: 16769937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component.
    Walker C; du Plessis DG; Fildes D; Haylock B; Husband D; Jenkinson MD; Joyce KA; Broome J; Kopitski K; Prosser J; Smith T; Vinjamuri S; Warnke PC
    Clin Cancer Res; 2004 Nov; 10(21):7182-91. PubMed ID: 15534091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
    van den Bent MJ; Looijenga LH; Langenberg K; Dinjens W; Graveland W; Uytdewilligen L; Sillevis Smitt PA; Jenkins RB; Kros JM
    Cancer; 2003 Mar; 97(5):1276-84. PubMed ID: 12599236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours.
    Jenkinson MD; Smith TS; Joyce KA; Fildes D; Broome J; du Plessis DG; Haylock B; Husband DJ; Warnke PC; Walker C
    Neuroradiology; 2006 Oct; 48(10):703-13. PubMed ID: 16937145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
    Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
    Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
    Buckner JC; Gesme D; O'Fallon JR; Hammack JE; Stafford S; Brown PD; Hawkins R; Scheithauer BW; Erickson BJ; Levitt R; Shaw EG; Jenkins R
    J Clin Oncol; 2003 Jan; 21(2):251-5. PubMed ID: 12525516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathology and clinical characteristics of oligodendroglial neoplasms.
    Walker C; du Plessis DG; Joyce KA; Fildes D; Gee A; Haylock B; Husband D; Smith T; Broome J; Warnke PC
    Ann Neurol; 2005 Jun; 57(6):855-65. PubMed ID: 15929038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features.
    Jenkinson MD; du Plessis DG; Smith TS; Joyce KA; Warnke PC; Walker C
    Brain; 2006 Jul; 129(Pt 7):1884-91. PubMed ID: 16670176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
    Kouwenhoven MC; Kros JM; French PJ; Biemond-ter Stege EM; Graveland WJ; Taphoorn MJ; Brandes AA; van den Bent MJ
    Eur J Cancer; 2006 Oct; 42(15):2499-503. PubMed ID: 16914310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
    Kouwenhoven MC; Gorlia T; Kros JM; Ibdaih A; Brandes AA; Bromberg JE; Mokhtari K; van Duinen SG; Teepen JL; Wesseling P; Vandenbos F; Grisold W; Sipos L; Mirimanoff R; Vecht CJ; Allgeier A; Lacombe D; van den Bent MJ
    Neuro Oncol; 2009 Dec; 11(6):737-46. PubMed ID: 19224764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
    van den Bent MJ; Carpentier AF; Brandes AA; Sanson M; Taphoorn MJ; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Haaxma-Reiche H; Kros JM; van Kouwenhoven MC; Vecht CJ; Allgeier A; Lacombe D; Gorlia T
    J Clin Oncol; 2006 Jun; 24(18):2715-22. PubMed ID: 16782911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anaplastic oligodendroglial tumors harboring 1p/19q deletion can be successfully treated without radiotherapy.
    Iwadate Y; Matsutani T; Shinozaki N; Saeki N
    Anticancer Res; 2011 Dec; 31(12):4475-9. PubMed ID: 22199318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes.
    Jenkinson MD; Smith TS; Joyce K; Fildes D; du Plessis DG; Warnke PC; Walker C
    Neurology; 2005 Jun; 64(12):2085-9. PubMed ID: 15985578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
    ; Cairncross G; Berkey B; Shaw E; Jenkins R; Scheithauer B; Brachman D; Buckner J; Fink K; Souhami L; Laperierre N; Mehta M; Curran W
    J Clin Oncol; 2006 Jun; 24(18):2707-14. PubMed ID: 16782910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
    Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A;
    Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.
    Cairncross JG; Ueki K; Zlatescu MC; Lisle DK; Finkelstein DM; Hammond RR; Silver JS; Stark PC; Macdonald DR; Ino Y; Ramsay DA; Louis DN
    J Natl Cancer Inst; 1998 Oct; 90(19):1473-9. PubMed ID: 9776413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic.
    van den Bent MJ
    Am Soc Clin Oncol Educ Book; 2013; ():114-6. PubMed ID: 23714473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.
    Parkinson JF; Afaghi V; Payne CA; Buckland ME; Brewer JM; Biggs MT; Little NS; Wheeler HR; Cook RJ; McDonald KL
    J Clin Neurosci; 2011 Mar; 18(3):329-33. PubMed ID: 21247767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eighty percent survival rate at 15 years for 1p/19q co-deleted oligodendroglioma treated with upfront chemotherapy irrespective of tumor grade.
    Iwadate Y; Matsutani T; Hara A; Hirono S; Ikegami S; Kobayashi M; Ito D; Kawauchi D; Horiguchi K; Tamiya A; Higuchi Y
    J Neurooncol; 2019 Jan; 141(1):205-211. PubMed ID: 30565028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.